Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...
Eli Lilly's (LLY.N), opens new tab high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the ...
Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling ... Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro, and weight-loss drug Zepbound.
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
An injection pen of Zepbound, Eli Lilly’s weight-loss drug, is displayed in New York City ... for its injectable obesity drug Zepbound and diabetes medicine Mounjaro combined, raising concerns ...